Page last updated: 2024-11-13
gonyautoxin ii
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
gonyautoxin II: RN given refers to (3aS-(3aalpha,4alpha,9beta,10aR*))-isomer; gonyautoxin III is the (9alpha)-isomer of gonyautoxin II [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 101650338 |
CHEBI ID | 80769 |
MeSH ID | M0127750 |
Synonyms (18)
Synonym |
---|
gonyautoxin ii |
60508-89-6 |
gonyautoxin 2 |
unii-yu77z3ny6z |
toxin gtx2 |
11alpha-hydroxysaxitoxin 11-sulfate |
yu77z3ny6z , |
gtx2 |
gtx ii |
1h,10h-pyrrolo(1,2-c)purine-9,10,10-triol, 2,6-diamino-4-(((aminocarbonyl)oxy)methyl)-3a,4,8,9-tetrahydro-, 9-(hydrogen sulfate), (3as,4r,9r,10as)- |
CHEBI:80769 |
1h,10h-pyrrolo(1,2-c)purine-9,10,10-triol, 2,6-diamino-4-(((aminocarbonyl)oxy)methyl)-3a,4,8,9-tetrahydro-, 9-(hydrogen sulfate), (3as-(3a.alpha.,4.alpha.,9.beta.,10ar*))- 11.alpha.-hydroxysaxitoxin 11-sulfate |
gonyautoxin iim |
gonyautoxin-2 |
[(3as,4r,9r,10as)-10,10-dihydroxy-2,6-diimino-9-(sulfooxy)octahydro-1h,8h-pyrrolo[1,2-c]purin-4-yl]methyl carbamate |
Q27149819 |
toxin gtx2;gtx ii; gtx2; gonyautoxin 2 |
[(3as,4r,9r,10as)-2,6-diamino-10,10-dihydroxy-9-sulfooxy-3a,4,8,9-tetrahydro-1h-pyrrolo[1,2-c]purin-4-yl]methyl carbamate |
Research Excerpts
Toxicity
Excerpt | Reference | Relevance |
---|---|---|
" Therefore, populations utilizing high ammonium concentration could be more toxic than those growing on nitrate or urea." | ( Variability in toxicity of the dinoflagellate Alexandrium tamarense in response to different nitrogen sources and concentrations. Leong, SC; Murata, A; Nagashima, Y; Taguchi, S, 2004) | 0.32 |
"The therapeutic properties of gonyautoxin local infiltration in chronic tension-type headache patients are shown to be safe and effective." | ( Local infiltration of gonyautoxin is safe and effective in treatment of chronic tension-type headache. García, C; Lagos, M; Lagos, N; Lattes, K; Pedraza, L; Rodriguez-Navarro, AJ; Venegas, P, 2009) | 0.35 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (1)
Role | Description |
---|---|
marine metabolite | Any metabolite produced during a metabolic reaction in marine macro- and microorganisms. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (2)
Class | Description |
---|---|
organic heterotricyclic compound | An organic tricyclic compound in which at least one of the rings of the tricyclic skeleton contains one or more heteroatoms. |
paralytic shellfish toxin | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (16)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (6.25) | 18.7374 |
1990's | 1 (6.25) | 18.2507 |
2000's | 8 (50.00) | 29.6817 |
2010's | 6 (37.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.43
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.43) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (6.25%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 15 (93.75%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |